Peter Zhang: Is Canada Ready for the Gene Therapy Era?
Peter Zhang, Director, Business Acceleration at Odaia, shared a post on LinkedIn:
”My latest in The Hill Times on gene therapies, and whether the Canadian healthcare system is ready for these innovative medicines.
When I was a board member with Hemophilia Ontario (now known as Bleeding Disorders Ontario), I was excited to hear about its patient impact firsthand.
This year, a Canadian with severe hemophilia B received the first gene therapy approved in Canada. But a single dose can cost more than $4 million, and payers need to approach patient access in an equitable and sustainable manner.
Canada also needs to consider its strategy for future innovations in gene therapy and it’s encouraging that there is ongoing work to leverage this technology to introduce therapies for patients living with Huntington’s disease, spinal muscular atrophy, and inherited retinal diseases.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT